Sanofi (SNYNF)
| Market Cap | 122.66B |
| Revenue (ttm) | 53.71B |
| Net Income (ttm) | 10.72B |
| Shares Out | n/a |
| EPS (ttm) | 8.65 |
| PE Ratio | 11.44 |
| Forward PE | 10.77 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 454 |
| Average Volume | 10,875 |
| Open | 98.29 |
| Previous Close | 95.03 |
| Day's Range | 98.29 - 100.19 |
| 52-Week Range | 90.05 - 122.03 |
| Beta | 0.44 |
| RSI | 57.29 |
| Earnings Date | Oct 24, 2025 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial numbers in EUR Financial StatementsNews
Sanofi's Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease
On Friday, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for Sanofi SA’s (NASDAQ: SNY) Rezurock (belumosudil). The French drug maker ...
Sanofi (SNY) Gets EMA Backing for New Drug for Immune Thrombocytopenia
Sanofi (SNY) Gets EMA Backing for New Drug for Immune Thrombocytopenia
Sanofi and Insmed among winners of EU drug recommendations this week
Sanofi (SNY) Seeks Re-Examination of EU Decision on Rezurock for cGVHD
Sanofi (SNY) Seeks Re-Examination of EU Decision on Rezurock for cGVHD
Press Release: Sanofi's Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
Sanofi's Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia Recommendation based on LUNA 3 phase 3 study demonstrating rapid and durable platelet response and significant...
Press Release: Sanofi's Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
Sanofi's Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia Recommendation based on LUNA 3 phase 3 study demonstrating rapid and durable platelet response and significant...
Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease Paris, October 17, 2025. The European Medicines Agency's Committee for Medicinal Products for ...
Genzyme Ireland Ltd, the Irish arm of biopharma giant Sanofi, pays out 800m dividend as profits soar to over 328m
The main Irish arm of biopharma giant Sanofi last year paid out dividends of 800m.
EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi
CHICAGO , Oct. 16, 2025 /PRNewswire/ -- EVOQ Therapeutics, Inc. (EVOQ), a biotechnology company focused on delivering transformative cures for those living with autoimmune diseases, today announced a ...
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential
Shah Capital is reportedly pressing Novavax Inc. (NASDAQ: NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine . • NVAX stock is showing exc...
ITM Appoints Annette Breunig as Chief People Officer
Garching / Munich, Germany, October 13, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Annette Breunig as Chief Peop...
Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out
Shares of Apogee Therapeutics have gained 34% over the past two days as the small biotech looks to take on Regeneron and Sanofi.
Sanofi and Orano Med succeed in mid-stage trial for neuroendocrine tumor therapy
Sanofi (SNY) stock is in focus as its AlphaMedix therapy developed with Orano Med succeeds in a mid-stage trial for neuroendocrine tumors. Read more here.
BenchSci Announces Three-Year License Agreement with Sanofi to Access and Use BenchSci's ASCEND Platform
TORONTO--(BUSINESS WIRE)--BenchSci Announces Three-Year License Agreement with Sanofi to Access and Use BenchSci's ASCEND Platform.
Sanofi's AlphaMedix Shows Strong Phase 2 Results For Advanced Neuroendocrine Tumor Treatment
(RTTNews) - Sanofi SA (SNY, SNYNF, SAN.PA) announced promising results from its ALPHAMEDIX-02 Phase 2 clinical trial evaluating AlphaMedix (212Pb-DOTAMTATE), a novel somatostatin receptor-targeted alp...
Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
AlphaMedix TM ( 212 Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
Novavax (NVAX) Transfers EU Vaccine Rights to Sanofi for $25M
Novavax (NVAX) Transfers EU Vaccine Rights to Sanofi for $25M
Novavax hands over Nuvaxovid marketing rights to Sanofi in the EU
Sanofi (SNY) Gains Full EU Control of Nuvaxovid from Novavax
Sanofi (SNY) Gains Full EU Control of Nuvaxovid from Novavax
AstraZeneca Taps Gene Editing And AI Platform For Drug Discovery For Immunology Diseases
Algen Biotechnologies , a privately held biotech company specializing in advanced CRISPR gene modulation and AI-driven drug discovery, has announced a multi-target partnership with AstraZeneca Plc (NA...
Sanofi: Undervalued 2026 Pipeline, And Solid Results (Rating Upgrade)
Bullish Two Hundred Day Moving Average Cross - SNY
In trading on Friday, shares of Sanofi (Symbol: SNY) crossed above their 200 day moving average of $50.89, changing hands as high as $51.05 per share. Sanofi shares are currently trading up about 1.7%...
Sanofi (SNY) Supports Revvity's Expansion in Type 1 Diabetes Assay
Sanofi (SNY) Supports Revvity's Expansion in Type 1 Diabetes Assay
Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with s...
Sanofi (SNY) Under EU Antitrust Investigation Over Vaccine Practices
Sanofi (SNY) Under EU Antitrust Investigation Over Vaccine Practices